Jiangxi Copper (600362.SH) subsidiary's formal tender offer to acquire all shares of SolGold plc has taken effect.
Jiangxi Copper Corporation Limited (600362.SH) has announced that on December 24, 2025 (London local time), it will acquire SolGold plc through its wholly-owned subsidiary Jiangxi Copper (Hong Kong) Investment Limited (hereinafter referred to as Jiangxi Copper Hong Kong Investment) for 28 pence per share in cash for all issued and to be issued share capital of the target company (excluding shares already held by the company) by way of a formal offer.
Jiangxi Copper (600362.SH) announced that on December 24, 2025 (London local time), the company, through its wholly-owned subsidiary Jiangxi Copper (Hong Kong) Investment Limited (hereinafter referred to as Jiangxi Copper Hong Kong Investment), made a formal offer to acquire all of the issued and to be issued share capital of SolGold plc (hereinafter referred to as the target company) at 28 pence per share in cash. The company disclosed the progress of this formal offer acquisition on February 24, 2026, and March 3, 2026. The ruling made by the UK court on March 2, 2026 (London local time) was submitted to the UK Companies Registry on March 4, 2026 (London local time), and the acquisition scheme became effective on the day of submission.
The core asset of the target company, the Alpala deposit of the Cascabel project, has completed its pre-feasibility study, with confirmed, controlled, and inferred resources of 12.2 million tons of copper, 30.5 million ounces of gold, and 102.3 million ounces of silver, including confirmed and approximate reserves of 3.2 million tons of copper, 9.4 million ounces of gold, and 28 million ounces of silver.
It is expected that this transaction will significantly increase the company's resource reserves and resource security capability, support the company's overseas strategy, and facilitate the global layout of the company's resources, creating a broader space for the company to achieve high-quality sustainable development and enhance long-term core competitiveness.
Related Articles

HK Stock Market Move | CSTONE PHARMA-B(02616) rose by over 12%, the company's independently developed PD-1/VEGF/CTLA-4 triple antibody is expected to achieve a major breakthrough.

HK Stock Market Move | AKESO-B(09926) rose more than 6% in early trading as it collaborates with the US-based INOVIO in exploring innovative treatments for glioblastoma using new DNA drugs.
HK Stock Market Move | ANTENGENE-B(06996) rose by over 11%, reaching a nearly $1.2 billion authorization agreement with Usher.
HK Stock Market Move | CSTONE PHARMA-B(02616) rose by over 12%, the company's independently developed PD-1/VEGF/CTLA-4 triple antibody is expected to achieve a major breakthrough.

HK Stock Market Move | AKESO-B(09926) rose more than 6% in early trading as it collaborates with the US-based INOVIO in exploring innovative treatments for glioblastoma using new DNA drugs.

HK Stock Market Move | ANTENGENE-B(06996) rose by over 11%, reaching a nearly $1.2 billion authorization agreement with Usher.
RECOMMEND





